Posted by Michael Wonder on 21 Jul 2023
Excision BioTherapeutics receives FDA fast track designation for EBT-101, a first in class CRISPR based gene therapy candidate to functionally cure HIV-1
20 July 2023 - EBT-101 is a potentially curative, one time CRISPR based treatment which makes two cuts in integrated retroviral DNA to remove large portions of the HIV genome and prevent HIV from escaping and reproducing.
Excision BioTherapeutics today announced that the US FDA has granted fast track designation for its CRISPR based therapy, EBT-101, a dual cut CRISPR based gene therapy for the treatment of human immunodeficiency virus type 1.
